Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial

Autor: Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D. Smith

Publikováno v: Haematologica, Vol 999, Iss 1 (2024)

This multicenter, open-label, phase 1b study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naive (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients received acal

Externí odkaz: https://doaj.org/article/19f79693265c45379007ce9489c9f51a

PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES

Autor: Constantine Tam, Mazyar Shadman, Jeff Sharman, Gavin Cull, Tycel Phillips, Judith Trotman, Aileen Cohen, Heather Allewelt, Rocco Crescenzo, Richard Delarue, Heather Zhang, Bilal Tariq, Sri Sahasranaman, Ying C Ou, Ian W Flinn

Publikováno v: HemaSphere, Vol 7, p e70124b5 (2023)

Externí odkaz: https://doaj.org/article/8d11dcd7c056425c884e00b51e99bc6f

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

Autor: Thomas F Gajewski, John A Thompson, Sanjay Goel, Brendan D Curti, Elisabeth I Heath, Olivier Rixe, David C Smith, Celine Jacquemont, Tycel Phillips, Martin Gutierrez, Sahar Ansari, Andrew L Coveler, Svetomir N Markovic, Timothy M Kuzel, Amitkumar N Mehta, David L Bajor, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt, Juneko E Grilley-Olson

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)

Background SEA-CD40 is an investigational, non-fucosylated, humanized monoclonal IgG1 antibody that activates CD40, an immune-activating tumor necrosis factor receptor superfamily member. SEA-CD40 exhibits enhanced binding to activating FcγRIIIa, po

Externí odkaz: https://doaj.org/article/997d45d0420040f2a6abbe4400763c7d

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma

Autor: Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres, Chan Y. Cheah, Michael Roost Clausen, David Cunningham, Young Rok Do, Tatyana Feldman, Robin Gasiorowski, Wojciech Jurczak, Tae Min Kim, David John Lewis, Marjolein van der Poel, Michelle Limei Poon, Mariana Cota Stirner, Nurgul Kilavuz, Christopher Chiu, Menghui Chen, Mariana Sacchi, Brian Elliott, Tahamtan Ahmadi, Martin Hutchings, Pieternella J. Lugtenburg

Publikováno v: Journal of Clinical Oncology, 41(12), 2238-2247. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(12):JCO2201725, 2238-2247. American Society of Clinical Oncology

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d2ea84f20f4ef85a0e2e11b4d9597ef
https://cris.maastrichtuniversity.nl/en/publications/d1fc36c2-2d89-45b9-a114-20f08c25faba

Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial

Autor: John M Burke, Kristina S Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Tycel Phillips

Publikováno v: Journal of Managed Care & Specialty Pharmacy. 29:314-323

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::20cdb2fa9a76b63f6685c7c2b6e1be53
https://doi.org/10.18553/jmcp.2023.29.3.314